Immunobiology of Uveal Melanoma: State of the Art and Therapeutic Targets

Maria Sofia Basile, Emanuela Mazzon, Paolo Fagone, Antonio Longo, Andrea Russo, Matteo Fallico, Vincenza Bonfiglio, Ferdinando Nicoletti, Teresio Avitabile, Michele Reibaldi

Research output: Contribution to journalReview articlepeer-review


Uveal Melanoma (UM) represents the most common primary intraocular malignant tumor in adults. Although it originates from melanocytes as cutaneous melanoma, it shows significant clinical and biological differences with the latter, including high resistance to immune therapy. Indeed, UM can evade immune surveillance via multiple mechanisms, such as the expression of inhibitory checkpoints (e.g., PD-L1, CD47, CD200) and the production of IDO-1 and soluble FasL, among others. More in-depth understanding of these mechanisms will suggest potential targets for the design of novel and more effective management strategies for UM patients.

Original languageEnglish
Article number1145
JournalFrontiers in Oncology
Publication statusPublished - Nov 5 2019


  • immune-escape
  • immune-privilege
  • immunotherapy
  • inhibitory checkpoints
  • uveal melanoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Immunobiology of Uveal Melanoma: State of the Art and Therapeutic Targets'. Together they form a unique fingerprint.

Cite this